Yangxin Tongluo Decoction Protects Against Sepsis‐Associated Cardiac Dysfunction Through Regulating Nrf2 Pathway
Mediators of Inflammation · 2026-01 · 2026 (1)
DOI: 10.1155/mi/2804249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 23.07.2026. Verfasst von Hainan Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, 358 Datong Road Pudong New Di…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Sepsis, NF-E2-Related Factor 2. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Program of Shanghai Pudong New Area Health Commission, National Traditional Chinese Medicine Advantageous Specialty Construction, Research on Standardized Integrated Chinese and Western Medicine Diagnosis and Treatment Protocols for Electrochemical Thermal Injury.
Themen: Sepsis
Abstract (Originalsprache)
Background
Sepsis‐induced cardiac dysfunction is a major cause of high mortality in critically ill patients. Yangxin Tongluo decoction (YXTLD), a traditional Chinese medicine (TCM) formula, is clinically used for such conditions, but its therapeutic effects and underlying mechanisms remain unclear. This study investigated the protective role of YXTLD against sepsis‐associated cardiac dysfunction and its relationship with the Nrf2 signaling pathway.
Methods
An in vivo model of sepsis was established in male C57BL/6 mice via intraperitoneal lipopolysaccharide (LPS) injection. Cardiac function was assessed by echocardiography and serum biomarkers (creatine kinase [CK], lactate dehydrogenase [LDH]). In vitro, LPS‐stimulated H9c2 cardiomyocytes were treated with various doses of YXTLD. Cell viability, inflammation (interleukin [IL]‐1β, IL‐6, TNF‐α), oxidative stress (reactive oxygen species [ROS], malondialdehyde [MDA], catalase [CAT], glutathione [GSH]), and apoptosis were evaluated. The involvement of the Nrf2 pathway was examined using western blotting. In vivo dosage: YXTLD was administered intraperitoneally five times prior to LPS induction and continued after induction (total of seven doses over 48 h). In vitro concentrations: low (50 μg/mL), medium (100 μg/mL), and high (150 μg/mL) YXTLD.
Results
YXTLD significantly improved cardiac function and alleviated myocardial injury in septic mice, as evidenced by increased ejection fraction (EF; 97.87% ± 1.20% vs. 79.05% ± 3.04%) and fractional shortening (FS; 74.99% ± 5.58% vs. 41.98% ± 2.72%), together with reduced serum CK (188.60 ± 81.16 vs. 566.75 ± 186.24 U/L) and LDH (179.70 ± 54.47 vs. 463.65 ± 197.58 U/L) levels compared with the LPS group (all p < 0.05). In LPS‐stimulated H9c2 cells, YXTLD dose‐dependently enhanced cell viability, suppressed the expression of pro‐inflammatory cytokines (IL‐6, IL‐1β, and TNF‐α), reduced ROS production and lipid peroxidation, restored antioxidant capacity, and inhibited apoptosis. At 50 μg/mL, YXTLD markedly decreased IL‐6, IL‐1β, and TNF‐α levels by ~78%, 63%, and 92%, respectively (all p < 0.05). ROS and apoptotic cell proportions were progressively reduced with increasing YXTLD concentrations, reaching reductions of ~82% and 95%, respectively, at 150 μg/mL ( p < 0.001). Mechanistically, YXTLD activated the Nrf2 signaling pathway by promoting nuclear Nrf2 translocation and upregulating its downstream antioxidant proteins, including heme oxygenase‐1 (HO‐1), NAD(P)H quinone dehydrogenase 1 (NQO1), and glutamate‐cysteine ligase modifier (GCLM). YXTLD also restored CAT and GSH levels while reducing MDA accumulation, indicating attenuation of oxidative stress.
Conclusion
YXTLD protects against sepsis‐induced cardiac dysfunction by attenuating inflammation, oxidative stress, and apoptosis through activation of the Nrf2 signaling pathway. These findings provide a pharmacological basis for YXTLD as a potential therapeutic strategy for sepsis‐associated cardiac dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, 358 Datong Road Pudong New District, Shanghai 200137, China, shutcm.edu.cn.
- Department of Rehabilitation, Liuzao Community Health Service Center, Pudong New District, Shanghai 201322, China.
- Department of General Practice, Beicai Community Health Service Center, Pudong New District, Shanghai 201204, China.
ORCID-Profile: Hainan Yang, Beijing Wu, Die Huang, Hui Ye, Weifang Yuan, Lijiao You, Xueru Huang, Haikuo Wang, Yaoguo Han, Ming Lei
Förderung
- Scientific Research Program of Shanghai Pudong New Area Health Commission
- National Traditional Chinese Medicine Advantageous Specialty Construction
- Research on Standardized Integrated Chinese and Western Medicine Diagnosis and Treatment Protocols for Electrochemical Thermal Injury
- Clinical Emergency Medicine Center Project of Shanghai Seventh People's Hospital
Zitieren
APA
Yang, H., Wu, B., Huang, D., Ye, H., Yuan, W., You, L., Huang, X., Wang, H., Han, Y., & Lei, M. (2026). Yangxin Tongluo Decoction Protects Against Sepsis‐Associated Cardiac Dysfunction Through Regulating Nrf2 Pathway. Mediators of Inflammation, 2026(1). https://doi.org/10.1155/mi/2804249
Vancouver
Yang H, Wu B, Huang D, Ye H, Yuan W, You L, et al. Yangxin Tongluo Decoction Protects Against Sepsis‐Associated Cardiac Dysfunction Through Regulating Nrf2 Pathway. Mediators of Inflammation. 2026;2026(1). doi:10.1155/mi/2804249
BibTeX
@article{Yang2026,
author = {Yang, Hainan and Wu, Beijing and Huang, Die and Ye, Hui and Yuan, Weifang and You, Lijiao and Huang, Xueru and Wang, Haikuo and Han, Yaoguo and Lei, Ming},
title = {Yangxin Tongluo Decoction Protects Against Sepsis‐Associated Cardiac Dysfunction Through Regulating Nrf2 Pathway},
journal = {Mediators of Inflammation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/mi/2804249}
}
EUVIMED